Auris Medical Holding to Present at LD Micro Invitational XI Conference
28 Maio 2021 - 9:30AM
Hamilton, Bermuda, May 28, 2021 – Auris Medical
Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to
developing therapeutics that address important unmet medical needs
in neurotology, rhinology and allergy and CNS disorders, today
announced that Chairman and CEO Thomas Meyer will present at the LD
Micro Invitational XI investor conference on Wednesday June 9,
2021, at 11:00 a.m. EST (Track 2). The event will be webcast live
and available via the event homepage
https://ldmicrojune2021.mysequire.com.
About Auris Medical
Auris Medical is a clinical-stage company
dedicated to developing therapeutics that address important unmet
medical needs in neurotology, rhinology and allergy and CNS
disorders. The Company is focused on the development of intranasal
betahistine for the treatment of vertigo (AM-125, in Phase 2) and
for the prevention of antipsychotic-induced weight gain and
somnolence (AM-201, post Phase 1b). Through its affiliate Altamira
Medica, the Company is developing a nasal spray for protection
against airborne viruses and allergens BentrioTM (AM-301). In
addition, Auris Medical has two Phase 3 programs under development:
Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen®
(AM-101) for acute inner ear tinnitus. The Company was founded in
2003 and is headquartered in Hamilton, Bermuda with its main
operations in Basel, Switzerland. The shares of Auris Medical
Holding Ltd. trade on the NASDAQ Capital Market under the symbol
“EARS.”
Investor contact:
investors@aurismedical.com
Auris Medical (NASDAQ:EARS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Auris Medical (NASDAQ:EARS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
Notícias em tempo-real sobre Auris Medical Holding AG da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de